Abstract
Patients suffering from rheumatoid arthritis (RA) may experience a temporary reduction of disease symptoms during pregnancy. As indicated by the occurrence of RA-disease symptoms during pregnancy, three categories of patients were defined, namely, remission, relapse and unchanged. In all three categories changes in the plasma level and glycosylation of α1-acid glycoprotein (AGP) were determined longitudinally in comparison to those occurring in pregnancy of healthy women. In healthy pregnancy, we observed: (i) a peak in the plasma concentration at week 18 and a minimum at week 30; (ii) a continuous increase in the degree of branching of the glycans during the entire pregnancy period, and (iii) a decrease in the degree of α3-fucosylation of AGP-glycans with a minimum occurring at week 25. Comparable pregnancy-induced changes in glycosylation were found for two other acute-phase proteins α1-protease inhibitor (PI) and α1-antichymotrypsin (ACT). Increased oestrogen levels, known to occur during pregnancy, may be one of the factors that induce these changes, because the increased branching and decreased α3-fucosylation is in agreement with our earlier findings regarding an involvement of this hormone in the regulation of acute phase protein glycosylation in oestrogen-treated males as well as females. In all three clinical categories in RA, pregnancy also induced a continuous increase in the degree of branching of the glycans of AGP. However, similar changes in concentration and fucosylation were only found during remission of the disease symptoms. In the relapse and unchanged categories in RA, the degree of fucosylation and the plasma concentration of AGP remained constant throughout pregnancy. This indicates a relationship between changes in α3-fucosylation of AGP and RA disease activity.
Similar content being viewed by others
References
Baumann H, Gauldie J (1994) Immunol Today 15: 74-80.
Turner GA (1992) Clin Chim Acta 208: 149-71.
Van Dijk W, Havenaar EC, Brinkman-Van der Linden ECM (1995) Glycoconjugate J 12: 227-33.
Fournet B, Montreuil J, Strecker G, Dorland L, Haverkamp J, Vliegenthart JFG, Binette JP, Schmid K (1977) Biochemistry 17: 5206-14.
Laine A, Hachulla E, Strecker G, Michalski J-C, Wieruszeski J-M (1991) Eur J Biochem 197: 209-15.
Mega T, Lujan E, Yoshida, A (1980) J Biol Chem 255: 4057-61.
Brinkman-Van der Linden ECM, Van Ommen ECR, Van Dijk W (1996) Glycoconjugate J 13: 27-31.
Raynes J (1982) Biomedicine 36: 77-86.
Mallet B, Franc JL, Miquel M, Arnaud C (1987) Clin Chim Acta 167: 247-57.
Brinkman-Van der Linden ECM, De Haan PF, Havenaar EC, Van Dijk W (1998) Glycoconjugate J 15: 177-82
Havenaar EC, Dolhain RJEM, Turner GA, Goodarzi MT, Van Ommen ECR, Breedveld FC, Van Dijk W (1997) GlycoconjugateJ 14: 457-65.
Thompson S, Dargan E, Griffiths ID, Kelly CA, Turner GA (1993) Clin Chim Acta 220: 107-14.
De Graaf TW, Van der Stelt ME, Anbergen MG, Van Dijk W (1993) J Exp Med 177: 657-66.
Dargan E, Thompson S, Cantwell BMJ, Wilson RG, Turner GA (1994) Glycosylation and Disease 1: 37-43.
De Graaf TW, Van Ommen ECR, Van der Stelt ME, Kerstens PJSM, Boerbooms AMT, Van Dijk W (1994) J Rheumatol 21: 2209-16.
Wells C, Bøg-Hansen TC, Cooper EH, Glass MR (1981) Clin Chim Acta 109: 59-67.
Brinkman-Van der Linden ECM, Havenaar EC, Van Ommen ECR, Van Kamp GJ, Gooren LJG, Van Dijk W (1996) Glycobiology 6: 407-12.
Lawrence JS (1970) Ann Rheum Diseases 29: 357-79.
Spector TD (1990) Rheumatoid arthritis. Rheum Dis Clin North Am 16: 513-37.
Vandenbroucke JP, Valkenburg HA, Boersma JW, Cats A, Festen JJM, Huber-Bruning O, Rasker JJ (1982) Lancet 2: 839-42.
Arnett FC, Edworthy SM, Bloch DA, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) Arthr Rheum 31: 315-24.
Camp AV (1972) Orthopaedics (Oxford) 4: 39-45.
Unger A, Kay A, Griffin AJ, Panayi GS (1983) Brit Med J Clin Res 286: 750-2.
Mancini G, Carbonara AO, Heremans JF (1965) Immunochemistry 2: 235-54.
Bøg-Hansen TC (1973) Anal Biochem 56: 480-8.
Goldstein I, Hayes CE (1978) Adv Carbohydr Chem Biochem 35: 127-340.
Bierhuizen M, De Wit M, Govers MC, Ferwerda W, Koeleman C, Van Dijk W (1988) Eur J Biochem 175: 387-94.
Brinkman-Van der Linden ECM, Mollicone R, Oriol R, Larson G, Van den Eijnden DH, Van Dijk W (1996) J Biol Chem 24: 14492-5.
Saitoh A, Aoyagi Y, Asakura H (1993) Arch Biochem Biophys 303: 281-7.
Lockitch G (1997) Critical Rev Lab Sci 34: 67-139.
Pos O, Oostendorp RAJ, Van der Stelt ME, Scheper RJ, Van Dijk W (1990) Inammation 14: 133-41.
Costello M, Fiedel BA, Gewurz, H (1979) Nature 281: 677-8.
Cid MC, Kleinman HK, Grant DS, Schnaper HW, Fauci AS, Hoffman GS (1994) J Clin Invest 93: 17-25.
Finn R, St Hill CA, Govan AJ, Ralfs IG, Gurney FJ, Denye V (1972) Brit Med J 3: 150-2.
Hu S-K, Mitcho YL, Rath NC (1988) J Immunopharmacol 10: 247-50.
Fox HS, Bond BL, Parslow TG (1991) J Immunol 146: 4362-7.
Tabibzadeh SS, Santhanam U, Sehgal PB, May LT (1989) J Immunol 142: 3134-9.
Ray P. Ghosh SK, Zhang DH, Ray A (1997) FEBS Lett 409: 79-85.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. (1998) Arthr Rheum 31: 315-24
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Havenaar, E.C., Axford, J.S., Brinkman-van der Linden, E.C. et al. Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in α3-fucosylation of α1-acid glycoprotein. Glycoconj J 15, 723–729 (1998). https://doi.org/10.1023/A:1006944700325
Issue Date:
DOI: https://doi.org/10.1023/A:1006944700325
- rheumatoid arthritis
- Pregnancy
- α-acid glycoproteinα1-anitchymotrypsin
- α1-protease inhibitor
- fucosylation
- AAL, Aleuria aurantia lectin
- ACT, α1-antichymotrypsin
- AGP, α1-acid glycoprotein
- APP, acute-phase protein
- A0, Aw and As, APP glycoforms that are non-reactive,weakly reactive, respectively, strongly reactive withAAL
- CAIE, crossed affino immunoelectrophoresis
- Con A, concanavalin A
- C0, Cw and Cs, APP glycoforms that are non-reactive,weakly reactive, respectively, strongly reactive withConA
- HSPC, human serum protein calibrator
- PI, α1-protease inhibitor
- RA, rheumatoid arthritis